A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases

Recruiting now · Phase 2

Conditions studied: Testicular Cancer

In brief

Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients

Key facts

Study ID

NCT06932458

Run by

Western University, Canada

People needed

30

Starts

2025-07-17

Expected to finish

2030-06-01

Last updated by the study team

2025-07-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (>18 years) with pure seminoma on radical orchiectomy specimen.
• Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation.
• Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND
• No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones.
• Suitable for proposed bilateral RPLND template
• Serum tumour markers (alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)) must all be within normal limits within 2 weeks of planned RPLND

You may not qualify if…

• Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection
• Any non-seminoma component on the orchiectomy specimen.
• AFP >20 at any time point, pre- or post-orchiectomy.

Where it is running

• London Health Sciences Centre — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.